403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Ozempic-Maker Novo Nordisk Says CEO To Step Down
(MENAFN- The Peninsula)
AFP
Copenhagen: Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday its chief executive was stepping down from his role.
"A search for Lars Fruergaard Jorgensen's successor is ongoing, and an announcement will be made in due course," the company said in a statement, adding that the decision had been a "mutual agreement with the Novo Nordisk board ... in light of the recent market challenges Novo Nordisk has been facing and the development of the company's share price since mid-2024".
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
- Zebec Network Acquires Science Card, Expanding Mission-Driven Finance For Universities
- Polemos Launches $PLMS Token On MEXC And Uniswap, Advancing Web3 Gaming Infrastructure
- Founders Of Layerzero, SEI, Selini Capital, And Plume Back Hyper-Personalized AI Crypto Discovery Engine
- B2PRIME Appoints Former Onezero Sales Head Stuart Brock As Institutional Business Development Manager
- B2BROKER Welcomes Former Salesforce And Linkedin Executive Moustapha Abdel Sater As Chief Commercial Officer
- FBS Analysts Link Fed Signals To A Potential Crypto Comeback
More Story
Comments
No comment